QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia — Stella

Home/Cancer Treatment-Induced Thrombocytopenia/

View on ClinicalTrials.gov

Recruiting

Back to Cancer Treatment-Induced Thrombocytopenia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

Harbin First Hospital, Harbin

Nanjing Tianyinshan Hospital, Nanjing

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Qilu Pharmaceutical Co., Ltd.

Enrollment target

~235 participants

Started

October 2024

Primary completion

July 2026

Age range

18 Years – 75 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.